CPRX FY 2024 Earnings — Catalyst Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

CPRXCatalyst Pharmaceuticals, Inc.

$3B

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$492M+23.5% YoY

Gross Profit

$423M86.0% margin

Operating Income

$195M39.7% margin

Net Income

$164M33.3% margin

EPS (Diluted)

$1.31

Cash Flow

Operating Cash Flow

$240M

Free Cash Flow

$239M

Stock-Based Comp.

$22M

Balance Sheet

Total Assets

$851M

Total Liabilities

$124M

Stockholders' Equity

$728M

Cash & Equivalents

$518M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$492M	$398M	+23.5%
Gross Profit	$423M	$346M	+22.1%
Operating Income	$195M	$87M	+124.8%
Net Income	$164M	$71M	+129.5%